1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Indoco Remedies Limited

Indoco Remedies Limited

INDOCO.BO
Indoco Remedies LimitedIN flagBombay Stock Exchange
238.00
INR
+2.05
- -
21.91BMarket Cap
Indoco Remedies Limited
INDOCO.BO
(Bombay Stock Exchange)

Recent

price

238.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
52.2
61.72
68.45
79.5
93
109.4
113.66
110.44
103.81
117.2
132.28
163.18
177.98
194.05
188.3
- -
206.21
Revenue per Share
5.55
5.03
4.64
6.29
8.99
8.89
8.36
4.47
-0.32
2.62
10.1
16.8
15.44
10.68
-8.46
- -
-10.95
Basic EPS, GAAP
-4.66
7.5
7.45
10.72
11.83
12.18
9.62
13.32
14.56
13.33
8.93
18.86
19.41
16.86
10.41
- -
- -
Free Cash Flow per Basic Share
1.09
1.24
1.27
1.29
1.64
3.58
0.26
1.92
1.22
0.36
0.3
1.5
2.25
2.25
1.59
- -
- -
Dividend per Share
30.3
14.17
16.55
19.58
25.55
29.19
35.7
38.26
37.27
38.76
48.48
63.19
76.53
84.97
79.23
- -
2.13
Book Value per Share
35.18
37.55
39.94
44.31
48.43
52.99
60.11
61.58
62.3
63.82
74.29
88.19
98.1
100.11
94.78
- -
84.18
Tangible Book Value per Share
92
92
92
92
92
92
92
92
91
92
92
92
92
92
87
- -
87
Basic Weighted Avg Shares
4,811
5,688
6,308
7,326
8,570
10,081
10,474
10,177
9,421
10,800
12,186
15,037
16,400
17,882
16,413
17,929
17,912
Sales/Revenue/Turnover
11.4
11.6
11.09
12.36
14.42
11.19
8
6.37
-0.99
4.48
13.06
14.65
12.05
7.99
-0.89
0.86
0.86
Operating Margin (%)
135
192
237
309
471
607
633
677
716
708
731
772
706
919
982
1,069
1,264
Depreciation Expense
511
463
427
580
828
819
771
412
-29
241
930
1,548
1,423
985
-737
-952
-952
Net Income, GAAP
9.66
9.6
11.92
19.75
24.4
17.17
15.26
14.95
- -
15.59
29.51
34.57
26.22
28.57
- -
- -
- -
Effective Tax Rate (%)
10.63
8.15
6.77
7.91
9.66
8.13
7.36
4.04
-0.31
2.23
7.64
10.29
8.67
5.51
-4.49
-5.31
-5.31
Profit Margin (%)
1,049
797
762
1,024
1,306
1,616
1,817
1,216
926
1,041
2,156
3,488
3,891
3,423
1,933
1,408
1,408
Working Capital
540
462
274
138
128
379
1,323
1,233
1,287
1,024
1,039
1,068
1,585
3,641
5,426
5,584
5,584
LT Debt
3,502
3,800
4,144
4,574
5,277
5,765
6,513
6,750
6,606
6,796
7,690
9,046
10,283
11,105
10,184
9,321
9,321
Total Equity
12.33
12.95
12.31
14.03
16.25
14.14
8.71
5.86
- -
4.32
11.36
13.23
11.78
6.63
- -
- -
- -
Return on Invested Capital (%)
14.08
20.34
17.43
26.35
30.53
25.04
17.66
8.92
- -
6.81
16.11
21.33
17.02
10.02
- -
- -
- -
Return on Capital (%)
17.34
22.62
30.17
34.83
39.83
32.49
25.78
12.08
-0.84
6.94
23.15
30.09
22.1
13.23
-10.01
-26.84
-26.84
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
5,047
- -
5,314
LT Borrowings
4,458
- -
5,160
LT Finance Leases
483
- -
423
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
- -
92
Market Capitalization
25,308
20,744
14,319

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
10,813
- -
11,934
Cash, Cash Equivalents & STI
232
- -
458
Accounts Receivable, Net
4,526
- -
4,892
Inventories
4,246
- -
4,052
Total Current Liabilities
9,850
- -
10,525
Payables & Accruals
- -
- -
- -
ST Debt
5,047
- -
5,314
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.3%
4.51%
-8.47%
Free Cash Flow
19.4%
41.8%
149.39%
Net Income, GAAP
-92.27%
-23.68%
29.03%
Sales/Revenue/Turnover
6.36%
8.5%
9.24%
Total Cash Common Dividend
74.19%
65.13%
-86.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,168
4,736
4,588
4,391
17,882
2025
4,243
4,307
4,024
3,839
16,413
2026
4,291
4,718
4,343
4,559
17,929

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.62
3.81
1.69
- -
10.68
2025
0.29
-1.09
-3.08
-4.48
-8.46
2026
-3.94
-1
-3.2
-2.57
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.25
2025
- -
- -
- -
- -
1.59
2026
- -
- -
- -
- -
- -
Similar Companies
Terra Tech Corp. (TRTC)
Neptune Wellness Solutions Inc. (NEPT.TO)
The Hash Corporation (REZN.CN)
Zhejiang Medicine Co., Ltd. (600216.SS)
NewBridge Global Ventures, Inc. (NBGV)
Adcock Ingram Holdings Limited (AIP.JO)
Business
Indoco Remedies Limited manufactures and markets formulations including finished dosage forms and active pharmaceutical ingredients for the pharmaceutical industry. The company offers products across categories such as stomatological including Sensodent-K, gastrointestinal including Cyclopam and Cital, respiratory including Febrex Plus, anti-infectives, vitamins minerals and nutrients, ophthalmological and ontological, dermatological, urological, anti-diabetic, gynaecological, lifestyle management, pain and analgesic, and cardiac therapies; it also provides branded generics like analgesic tablets and topical preparations, anti-hypertensives, protein supplements, multivitamin tablets and syrups, antibiotic tablets syrups and injectables, oral rehydration powders, antacids, antihistaminics, anti-haemorrhoidal creams, and calcium preparations, alongside contract research services encompassing custom synthesis analytical method development and stability studies, and contract manufacturing. Founded in 1947 and headquartered in Mumbai India with manufacturing facilities in Goa Baddi Waluj and Patalganga the company operates in over 55 countries including the United States United Kingdom Europe Australia New Zealand South Africa and others serving domestic and international generic markets through a network of over 3000 stockists and 150000 retailers in India. In December 2024 Indoco Remedies announced a strategic partnership with UK-based Clarity Pharma to launch approximately 20 affordable high-quality products over the next 18 months strengthening its foothold in the UK pharmaceutical market while maintaining existing B2B relationships; the company also pursues a robust pipeline of over 20 ANDAs with 4-5 annual launches and continues capex investments for growth having previously acquired Florida Pharmaceutical in the US for direct market presence.